Managed Access Programs for SEG101, Crizanlizumab

NCT03720626 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: crizanlizumab

Sponsor

Novartis Pharmaceuticals